Canaccord Genuity Q4 Med-Tech Preview: Best Ideas (HTWR & EW)
Tweet
Share
E-mailGet Alerts HTWR Hot Sheet
Price: $57.98 --0%
Rating Summary:
5 Buy, 14 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
5 Buy, 14 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity Q4 Med-Tech Preview: Best Ideas by Jason R. Mills
Our best ideas in 2012 (reiterated):
HeartWare (Nasdaq: HTWR)(BUY): Already pre-announced Q4 revenue. HTWR is on the verge of getting its first device approved in the US. We remain long-term bullish on the LVAD space and believe that HTWR is the stock to own.
Edwards Lifesciences (NYSE: EW)(BUY): TAVI stocking could boost Q4. Expect EW to communicate even more confidence in TA approval based on CAP performance.
Separately, Mills listed four companies that could report worse-than-expected Q4 results and/or 2012 guidance
IMRIS (Nasdaq: IMRS)(BUY): No announced bookings during Q4; OUS possible.
LeMaitre Vascular (Nasdaq: LMAT)(BUY): Still going through the transition away from endovascular. We would be buyers on further weakness.
St. Jude Medical (NYSE: STJ)(HOLD): Pre-announced in-line Q4; CRM (50% of sales) continuesto be weak which could cause management to reassess ’12 guidance.
Volcano (Nasdaq: VOLC)(HOLD): Pre-announced lower Q4 revenue owing to lackluster industrial business trends. However, FFR business is performing very well.
Our best ideas in 2012 (reiterated):
HeartWare (Nasdaq: HTWR)(BUY): Already pre-announced Q4 revenue. HTWR is on the verge of getting its first device approved in the US. We remain long-term bullish on the LVAD space and believe that HTWR is the stock to own.
Edwards Lifesciences (NYSE: EW)(BUY): TAVI stocking could boost Q4. Expect EW to communicate even more confidence in TA approval based on CAP performance.
Separately, Mills listed four companies that could report worse-than-expected Q4 results and/or 2012 guidance
IMRIS (Nasdaq: IMRS)(BUY): No announced bookings during Q4; OUS possible.
LeMaitre Vascular (Nasdaq: LMAT)(BUY): Still going through the transition away from endovascular. We would be buyers on further weakness.
St. Jude Medical (NYSE: STJ)(HOLD): Pre-announced in-line Q4; CRM (50% of sales) continuesto be weak which could cause management to reassess ’12 guidance.
Volcano (Nasdaq: VOLC)(HOLD): Pre-announced lower Q4 revenue owing to lackluster industrial business trends. However, FFR business is performing very well.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- DA Davidson Starts Everus (ECG) at Buy
- DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
